Novartis Ag (NVSEF) Restructuring Costs (2018)
Novartis Ag's (NVSEF) quarterly Restructuring Costs came in at -$33.0 million in Q3 2018, down 312.5% quarter-over-quarter from -$8.0 million in Q2 2018.
Novartis Ag (NVSEF) Restructuring Costs (2018) Analysis & Trends
Novartis Ag has disclosed Restructuring Costs across 1 years of filings, most recently posting -$33.0 million for Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -33.00 Mn |
| Jun 30, 2018 | -8.00 Mn |